OpenAlex
PricingAboutJobs
Log inGet started
Work

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

HTML

Year: 2019
Type: article
Source: Cancer Discovery
DOI: 10.1158/2159-8290.cd-19-0367
Authors: Megan A. Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, Emily Rozsahegyi, Nooreen Rubin, Michael P. Sheets, Joseph L. Kim, Chandrasekhar Miduturu, Neil Bifulco, Natasja Brooijmans, Hongliang Shi, Timothy Guzi, Andy Boral, Christoph Lengauer, Marion Dorsch, Richard D. Kim, Yoon-Koo Kang, Beni B. Wolf, Klaus P. Hoeflich
Institutions: Blueprint Medicines (United States), Moffitt Cancer Center, Asan Medical Center, University of Ulsan
Language: English

Topic: Fibroblast Growth Factor Research
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: hepatocellular carcinoma, FGFR4, FGF19, acquired drug resistance, gatekeeper mutation, oncogenic drivers, targeted therapy, pan-FGFR inhibitor
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2978029751
FWCI: 3.745
Cites: 26
Cited by: 121
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security